{'fraction_non_alphanumeric': 0.025703794369645042, 'fraction_numerical': 0.009791921664626682, 'mean_word_length': 6.077922077922078, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cell‐type Selective Phototoxicity Achieved with Chlorophyll‐a Derived Photosensitizers in a Co‐culture System of Primary Human Tumor and Normal Lung Cells

The ATP‐dependent transporter ABCG2 exports certain photosensitizers (PS) from cells, implying that the enhanced expression of ABCG2 by cancer cells may confer resistance to photodynamic therapy (PDT) mediated by those PS. In 35 patient‐derived primary cultures of lung epithelial and stromal cells, PS with different subcellular localization and affinity for ABCG2 displayed cell‐type specific retention both independent and dependent on ABCG2. In the majority of cases, the ABCG2 substrate 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a (HPPH) was lost from fibroblastic cells more rapidly than from their epithelial counterparts, even in the absence of detectable ABCG2 expression, facilitating selective eradication by PDT of epithelial over fibroblastic cells in tumor/stroma co‐cultures. Pairwise comparison of normal and transformed epithelial cells also identified tumor cells with elevated or reduced retention of HPPH, depending on ABCG2. Enhanced ABCG2 expression led to the selective PDT survival of tumor cells in tumor/stroma co‐cultures. This survival pattern was reversible through HPPH derivatives that are not ABCG2 substrates or the ABCG2 inhibitor imatinib mesylate. PS retention, not differences in subcellular distribution or cell signaling responses, was determining cell type selective death by PDT. These data suggest that up‐front knowledge of tumor characteristics, specifically ABCG2 status, could be helpful in individualized PDT treatment design.